Combined analysis of phenotypic and target-based screening in assay networks

Journal of Biomolecular Screening

Volumn 19, Issue 5, 2014, Pages 782-790

  Swamidass, S Joshua ^a   Schillebeeckx, Constantino N ^a   Matlock, Matthew ^a   Hurle, Mark R ^b   Agarwal, Pankaj ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Chemoinformatics; Database and data management; Pharmacology: ligand binding; Phenotypic drug discovery; Receptor binding; Statistical analyses

Indexed keywords

AMYLOID PRECURSOR PROTEIN; HISTONE DEACETYLASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KALLIKREIN 5; SUPEROXIDE DISMUTASE; ALOX15 PROTEIN, HUMAN; ARACHIDONATE 15 LIPOXYGENASE; LIPOXYGENASE INHIBITOR;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BINDING SITE; CELL DEATH; CELL PROLIFERATION; DRUG SCREENING; NERVE DEGENERATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; ALGORITHM; AREA UNDER THE CURVE; BIOASSAY; CHEMISTRY; DRUG DEVELOPMENT; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; MUTATION; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL;

ALGORITHMS; AMYOTROPHIC LATERAL SCLEROSIS; ARACHIDONATE 15-LIPOXYGENASE; AREA UNDER CURVE; BIOLOGICAL ASSAY; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIPOXYGENASE INHIBITORS; MODELS, STATISTICAL; MUTATION; PHENOTYPE; ROC CURVE;

EID: 84902124342     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114523068     Document Type: Article

References (26)

1. Wang, Y.; Xiao, J.; Suzek, T.; et al. PubChem: A Public Information System for Analyzing Bioactivities of Small Molecules. Nucleic Acids Res. 2009, 37, W623-W633
2. Swinney, D.; Anthony, J. How Were New Medicines Discovered? Nat. Rev. Drug Discov. 2011, 10, 507-519
3. Kotz, J. Small (Molecule) Thinking in Academia. SciBX: Science-Business eXchange 2011, 4
4. Baell, J.; Holloway, G. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. J. Med. Chem. 2010, 53, 2719-2740
5. Swamidass, S.; Calhoun, B.; Bittker, J.; et al. Utility-Aware Screening with Clique-Oriented Prioritization. J. Chem. Inf. Model. 2012, 52, 29-37
6. Swamidass, S.; Calhoun, B.; Bittker, J.; et al. Enhancing the Rate of Scaffold Discovery with Diversity-Oriented Prioritization. Bioinformatics 2011, 27, 2271-2278
7. Davis, B.; Erlanson, D. A. Learning from Our Mistakes: The "Unknown Knowns" in Fragment Screening. Bioorg. Med. Chem. Lett. 2013, 23, 2844-2852
8. Calhoun, B.; Browning, M.; Bittker, J.; et al. Automatically Detecting Workflows in PubChem. J. Biomol. Screen. 2012, 17, 1071-1079
9. Visser, U.; Abeyruwan, S.; Vempati, U.; et al. Bioassay Ontology (BAO): A Semantic Description of Bioassays and High-Throughput Screening Results. BMC Bioinformatics 2011, 12, 257
10. Chen, B.; McConnell, K.; Wale, N.; et al. Comparing Bioassay Response and Similarity Ensemble Approaches to Probing Protein Pharmacology. Bioinformatics 2011, 27, 3044-3049
11. Zhang, J.; Lushington, G.; Huan, J. The Bioassay Network and Its Implications to Future Therapeutic Discovery. BMC Bioinformatics 2011, 12, S1
12. Chen, B.; Wild, D.; Guha, R. PubChem as a Source of Polypharmacology. J. Chem. Inf. Model. 2009, 49, 2044- 2055
13. Hiemstra, D. A Probabilistic Justification for Using TF-IDF Term Weighting in Information Retrieval. Int. J. Digital Libraries 2000, 3, 131-139
14. Keiser, M.; Roth, B.; Armbruster, B.; et al. Relating Protein Pharmacology by Ligand Chemistry. Nat. Biotechnol. 2007, 25, 197-206 (Pubitemid 46227119)
15. Mattson, M. Cellular Actions of Beta-Amyloid Precursor Protein and Its Soluble and Fibrillogenic Derivatives. Physiol. Rev. 1997, 77, 1081-1132 (Pubitemid 27459580)
16. Paris, D.; Patel, N.; Quadros, A.; et al. Inhibition of A[beta] Production by nf-[kappa] b Inhibitors. Neurosci. Lett. 2007, 415, 11-16
17. Bales, K.; Du, Y.; Dodel, R.; et al. The NF-κb/Rel Family of Proteins Mediates Aβ-Induced Neurotoxicity and Glial Activation. Mol. Brain Res. 1998, 57, 63-72 (Pubitemid 28279561)
18. Li, Y.; Wang, H.; Wang, S.; et al. Positive and Negative Regulation of APP Amyloidogenesis by Sumoylation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 259
19. Dorval, V.; Fraser, P. SUMO on the Road to Neurodegeneration. Biochim. Biophys. Acta 2007, 1773, 694-706
20. Ono, K.; Nakane, H.; Fukushima, M.; et al. Differential Inhibitory Effects of Various Flavonoids on the Activities of Reverse Transcriptase and Cellular DNA and RNA Polymerases. Eur. J. Biochem. 1990, 190, 469-476
21. Ren, W.; Qiao, Z.; Wang, H.; et al. Flavonoids: Promising Anticancer Agents. Med. Res. Rev. 2003, 23, 519-534 (Pubitemid 36706514)
22. West, M.; Wang, H.; Wang, S.; et al. The Arachidonic Acid 5-Lipoxygenase Inhibitor Nordihydroguaiaretic Acid Inhibits Tumor Necrosis Factor α Activation of Microglia and Extends Survival of g93a-SOD1 Transgenic Mice. J. Neurochem. 2004, 91, 133-143 (Pubitemid 39314944)
23. Adcock, I. HDAC Inhibitors as Anti-Inflammatory Agents. Br. J. Pharmacol. 2007, 150, 829-831 (Pubitemid 46536629)
24. Johnstone, R. Histone-Deacetylase Inhibitors: Novel Drugs for the Treatment of Cancer. Nat. Rev. Drug Discov. 2002, 1, 287-299 (Pubitemid 37361445)
25. Borgono, C.; Michael, I.; Komatsu, N.; et al. A Potential Role for Multiple Tissue Kallikrein Serine Proteases in Epidermal Desquamation. J. Biol. Chem. 2007, 282, 3640-3652
26. Kim, H.; Scorilas, A.; Katsaros, D.; et al. Human Kallikrein Gene 5 (klk5) Expression Is an Indicator of Poor Prognosis in Ovarian Cancer. Br. J. Cancer. 2001, 84, 643-650. (Pubitemid 32238998)